Lonvoguran ziclumeran (lonvo-z)

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Epidemiology

3 evidence topics · 3 sources

Incidence of Hereditary angioedema